Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations (CHOICE)
A Six Month Double-blind, Randomised, Parallel-group, Placebo-controlled, Multi-centre Trial to Investigate the Efficacy and Safety of Two Ultra-low Dose Combinations With 0.5 mg Estradiol and 0.1 mg or 0.25 mg Norethisterone Acetate (Activelle Low Dose 0.1/Activelle Low Dose 0.25) for Treatment of Menopausal Symptoms
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Wien, Austria, A 1090
- Novo Nordisk Investigational Site
-
Wien, Austria, A 1060
- Novo Nordisk Investigational Site
-
-
-
-
-
Brussels, Belgium, 1200
- Novo Nordisk Investigational Site
-
Brussels, Belgium, 1000
- Novo Nordisk Investigational Site
-
Bruxelles, Belgium, 1180
- Novo Nordisk Investigational Site
-
Gent, Belgium, 9000
- Novo Nordisk Investigational Site
-
Huy, Belgium, 4500
- Novo Nordisk Investigational Site
-
Leuven, Belgium, 3000
- Novo Nordisk Investigational Site
-
Liège, Belgium, 4000
- Novo Nordisk Investigational Site
-
Montigny-Le-Tilleul, Belgium, 6110
- Novo Nordisk Investigational Site
-
Watermael-Boifort, Belgium, 1170
- Novo Nordisk Investigational Site
-
-
-
-
-
Allerød, Denmark, 3450
- Novo Nordisk Investigational Site
-
Frederiksberg, Denmark, 2000
- Novo Nordisk Investigational Site
-
Hvidovre, Denmark, 2650
- Novo Nordisk Investigational Site
-
København N, Denmark, 2400
- Novo Nordisk Investigational Site
-
Næstved, Denmark, 4700
- Novo Nordisk Investigational Site
-
Odense C, Denmark, 5000
- Novo Nordisk Investigational Site
-
Virum, Denmark, 2830
- Novo Nordisk Investigational Site
-
Århus C, Denmark, 8000
- Novo Nordisk Investigational Site
-
-
-
-
-
Espoo, Finland, 02200
- Novo Nordisk Investigational Site
-
Helsinki, Finland, 00100
- Novo Nordisk Investigational Site
-
Oulu, Finland, 90100
- Novo Nordisk Investigational Site
-
Tampere, Finland, 33101
- Novo Nordisk Investigational Site
-
Turku, Finland, 20100
- Novo Nordisk Investigational Site
-
-
-
-
-
Amiens, France
- Novo Nordisk Investigational Site
-
LA ROCHE-sur-YON cedex 9, France, 85295
- Novo Nordisk Investigational Site
-
MARSEILLE cedex 05, France, 13385
- Novo Nordisk Investigational Site
-
MONTPELLIER cedex 05, France, 34295
- Novo Nordisk Investigational Site
-
Marseille, France, 13004
- Novo Nordisk Investigational Site
-
Montpellier, France, 34000
- Novo Nordisk Investigational Site
-
NANTES cedex 1, France, 44093
- Novo Nordisk Investigational Site
-
NIMES cedex 9, France, 30000
- Novo Nordisk Investigational Site
-
Narbonne, France, 11108
- Novo Nordisk Investigational Site
-
Nice, France, 06000
- Novo Nordisk Investigational Site
-
Nimes, France, 30000
- Novo Nordisk Investigational Site
-
TOULOUSE cedex 9, France, 31059
- Novo Nordisk Investigational Site
-
-
-
-
-
Jessen, Germany, 06917
- Novo Nordisk Investigational Site
-
Karlsruhe, Germany, 76199
- Novo Nordisk Investigational Site
-
Leipzig, Germany, 04207
- Novo Nordisk Investigational Site
-
Lorsch, Germany, 64653
- Novo Nordisk Investigational Site
-
Rheine, Germany, 48431
- Novo Nordisk Investigational Site
-
Rheinstetten, Germany, 76287
- Novo Nordisk Investigational Site
-
Schorndorf, Germany, 73614
- Novo Nordisk Investigational Site
-
Stuttgart, Germany, 70563
- Novo Nordisk Investigational Site
-
Tübingen, Germany, 72076
- Novo Nordisk Investigational Site
-
Völklingen, Germany, 66333
- Novo Nordisk Investigational Site
-
-
-
-
-
Grålum, Norway, 1713
- Novo Nordisk Investigational Site
-
Hamar, Norway, NO-2317
- Novo Nordisk Investigational Site
-
Kolbotn, Norway, 1410
- Novo Nordisk Investigational Site
-
Lillestrøm, Norway, 2000
- Novo Nordisk Investigational Site
-
Oslo, Norway, 0309
- Novo Nordisk Investigational Site
-
Paradis, Norway, 5231
- Novo Nordisk Investigational Site
-
Stavanger, Norway, NO-4011
- Novo Nordisk Investigational Site
-
Stavanger, Norway, 4088
- Novo Nordisk Investigational Site
-
Trondheim, Norway, NO-7012
- Novo Nordisk Investigational Site
-
-
-
-
-
Göteborg, Sweden, 416 85
- Novo Nordisk Investigational Site
-
Göteborg, Sweden, 411 19
- Novo Nordisk Investigational Site
-
Linköping, Sweden, 581 85
- Novo Nordisk Investigational Site
-
Linköping, Sweden, 582 22
- Novo Nordisk Investigational Site
-
Lund, Sweden, 221 85
- Novo Nordisk Investigational Site
-
Malmö, Sweden, 217 44
- Novo Nordisk Investigational Site
-
Norrköping, Sweden, 602 32
- Novo Nordisk Investigational Site
-
Uppsala, Sweden, 751 85
- Novo Nordisk Investigational Site
-
-
-
-
-
Bulle, Switzerland, 1630
- Novo Nordisk Investigational Site
-
Frauenfeld, Switzerland, 8500
- Novo Nordisk Investigational Site
-
Weinfelden, Switzerland, 8570
- Novo Nordisk Investigational Site
-
Zürich, Switzerland, 8091
- Novo Nordisk Investigational Site
-
Zürich, Switzerland, 8032
- Novo Nordisk Investigational Site
-
-
-
-
-
Aldershot, United Kingdom, GU12 5BA
- Novo Nordisk Investigational Site
-
Bexhill-on-Sea, United Kingdom, TN39 4SP
- Novo Nordisk Investigational Site
-
Birmingham, United Kingdom, BE9'1 2JL
- Novo Nordisk Investigational Site
-
Bolton, United Kingdom, BL1 6AF
- Novo Nordisk Investigational Site
-
Chesterfield, Derbyshire, United Kingdom, S40 4AA
- Novo Nordisk Investigational Site
-
Chippenham, United Kingdom, SN15 1HP
- Novo Nordisk Investigational Site
-
Cornwell, United Kingdom, TR1 2LZ
- Novo Nordisk Investigational Site
-
Coventry, United Kingdom, CV6 2FL
- Novo Nordisk Investigational Site
-
Devon, United Kingdom, BH15 2JB
- Novo Nordisk Investigational Site
-
Hastings, United Kingdom, TN34 3EY
- Novo Nordisk Investigational Site
-
Hull, United Kingdom, HU2 8PX
- Novo Nordisk Investigational Site
-
Linclolshire, United Kingdom, PE21 6PF
- Novo Nordisk Investigational Site
-
Liverpool, United Kingdom, L8 7SS
- Novo Nordisk Investigational Site
-
London, United Kingdom, SE1 9RT
- Novo Nordisk Investigational Site
-
London, United Kingdom, W12 0HS
- Novo Nordisk Investigational Site
-
London, United Kingdom, SE5 8RS
- Novo Nordisk Investigational Site
-
Manchester, United Kingdom, M13 0JH
- Novo Nordisk Investigational Site
-
Norfolk, United Kingdom, NR4 7UZ
- Novo Nordisk Investigational Site
-
Oxford, United Kingdom, OX3 9UD
- Novo Nordisk Investigational Site
-
Reading, United Kingdom, RG7 3SQ
- Novo Nordisk Investigational Site
-
Sheffield, United Kingdom, S1 2PJ
- Novo Nordisk Investigational Site
-
Stoke on Trent, United Kingdom, ST4 6QG
- Novo Nordisk Investigational Site
-
Suffolk, United Kingdom, IP33 1HE
- Novo Nordisk Investigational Site
-
WAtford, United Kingdom, HA1 3UJ
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Postmenopausal status
- Subject should have had a minimum of 7 moderate to severe hot flushes per day, or a minimum of 50 moderate to severe hot flushes per week, during the last 2 weeks of the run-in (screening) period.
- Subject with an intact uterus
Exclusion Criteria:
- In accordance with existing labelling for estrogen/progestogen combinations
- Body Mass Index (BMI) > 35.0 kg/m2
- Known alcohol or drug abuse, heavy smoking (more than 20 cigarettes a day)
- Currently using steroid hormones (except topical or inhalation glucocorticoid preparations) and drugs known to influence estrogen metabolism such as barbiturates, phenytoin, rifampicin, carbamazepin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo tablets for 24 weeks
|
|
Experimental: ALD 0.1
|
One tablet per day for 24 weeks
|
|
Experimental: ALD 0.25
|
One tablet per day for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in mean number of moderate to severe hot flushes per week
Time Frame: At week 8
|
At week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Urogenital symptoms
Time Frame: Week 0; week 24
|
Week 0; week 24
|
|
Vaginal cytology and pH
Time Frame: Week 0; week 24
|
Week 0; week 24
|
|
Bleeding profile
Time Frame: Week 0; week 24
|
Week 0; week 24
|
|
Adverse Events
Time Frame: Week 0; week 24
|
Week 0; week 24
|
|
Menopausal symptoms and quality of life (Greene Climacteric Scale)
Time Frame: Week 0; week 24
|
Week 0; week 24
|
|
Hot flush weekly weighted score
Time Frame: Week 0; week 24
|
Week 0; week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Sturdee DW, Archer DF, Rakov V, Lang E; CHOICE Study Investigators. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric. 2008 Feb;11(1):63-73. doi: 10.1080/13697130701852390.
- Lundstrom E, Bygdeson M, Svane G, Azavedo E, von Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric. 2007 Jun;10(3):249-56. doi: 10.1080/13697130701385805.
- Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007 Apr;10(2):120-31. doi: 10.1080/13697130701298107.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Estradiol
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
- Norethindrone
- Norethindrone Acetate
Other Study ID Numbers
Other Study ID Numbers
- ALD-1537
- 2004-000103-17 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.